Thinking the unthinkable on Covid vaccine approvals
With the EU regulator already reviewing two coronavirus vaccines, could it beat the US FDA to the punch?
Contingent value is back in vogue
This week another takeover included a CVR element, confirming a trend that has been gaining traction over the past year.
Curevac muddies the Moderna/Arbutus waters further
The markets try to figure out who really benefits from last week’s patent decision over a key mRNA technology.
The Covid-19 vaccine battle just got interesting
A patent claim against Arbutus is thrown out, threatening parts of Moderna’s mRNA technology – including its Covid-19 vaccine.
Biogen gives investors something else to ponder
The company’s chief financial officer leaves on the eve of its second-quarter earnings report; should investors be worried?
